Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 8Neoplasm Metastasis 6Breast Neoplasms 6Thyroid Neoplasms 4Prostatic Neoplasms 4Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Urinary Bladder Neoplasms 2Pleural Effusion 2Ovarian Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Medullary 2Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid cancer, medullary 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Relapsed Pediatric Solid Tumor 1Recurrence 1Rectal Neoplasms 1Precancerous Conditions 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Non-small Cell Lung Cancer Metastatic 1

Interventions

vandetanib 1ruxolitinib 1pazopanib 1fludarabine 1Vemurafenib 1Trastuzumab 1Sorafenib 1Imatinib Mesylate 1Ifosfamide 1Everolimus 1Etoposide 1Erlotinib Hydrochloride 1Dasatinib 1Cytarabine 1Crizotinib 1Carboplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Relapsed Pediatric Solid Tumor × vandetanib × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡